Overall remission rates demonstrated an increasing trend over time, reaching 67.5% at month 1, 87.5% at month 2, 97.5% at month 3, and 95% at month 6.
← all excerpts
Eltrombopag for the treatment of refractory connective tissue disease-related thrombocytopenia: a pilot study of 52 cases.
1
—
—